J&J's head-to-head PhI­II da­ta promise drug launch in­to crowd­ed MS mar­ket

J&J an­nounced pos­i­tive da­ta from a head-to-head Phase III tri­al squar­ing their S1P1 MS drug pones­i­mod against Sanofi’s Auba­gio, set­ting up an FDA fil­ing lat­er …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER